{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Number of unique patients who had a treatment related (possible, probable or definite) adverse events that were graded 3 or greater.","groups":[{"description":"TREATMENT PHASE (COURSES 1-8): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving less than PR also receive dexamethasone PO or IV weekly in courses 4-8.\n\nMAINTENANCE PHASE (COURSES 9-14): Patients receive carfilzomib IV over 30 minutes on days 1, 2, 15, and 16. Patients who received dexamethasone in the Treatment Phase continue to receive dexamethasone PO or IV weekly. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.\n\ncarfilzomib: Given IV\n\ndexamethasone: Given IV or PO\n\nlaboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Carfilzomib, Dexamethasone)"}],"paramType":"NUMBER","populationDescription":"All patients enrolled and received treatment.","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment, up to 2 years","title":"Treatment Related Adverse Events Grade 3 or Higher","type":"SECONDARY","unitOfMeasure":"participants"}